This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
T cells are the trained killers of the immune system and the driving force behind cancer immunotherapy. But the behavior of T cells is hard to predict: Some spring into action when prompted, while others become lethargic and aimless. This puzzling inconsistency is one of the main reasons immunotherapies don't work in most cancer patients.
To tackle this problem, Memorial Sloan Kettering Cancer Center (MSK) researchers have developed a new approach to better understand and predict T cell behavior. The team, led by computational biologists Benjamin Greenbaum, Ph.D., and Sohrab Shah, Ph.D., designed a statistical model to monitor T cell responses to immunotherapies, including therapeutic cancer vaccines.
By connecting a T cell's receptors—which can recognize antigens (protein fragments) on the surface of cancer cells—to how it behaves, the researchers hoped to address a fundamental question: How does a T cell's genetic identity (the unique genetic sequence of its receptor) relate to its biological behavior—and how does that behavior change with immunotherapy?
The researchers used a new computational method, called TCRi (for TCR information), to analyze data from more than 167,000 T cells from cancer patients who had received immunotherapy drugs called checkpoint inhibitors.
"This approach produces a standardized measurement that lets us compare results across different studies and clinical trials," Greenbaum says.
Source link







